Onco Actu du 14 septembre 2017

	1. Biologie
Mutational Signature Analysis Reveals Breast Cancers With Mismatch Repair Deficiencies [AACR] The main limitation of this study is that it is a technical analysis and the findings need to be tested in clinical trials. MMR deficiency is rare in breast cancer; the investigators found that only 1 to 2 percent of breast cancer tumors had MMR deficiency, Nik-Zainal noted.
	3.1 Prévention - Tabac
Tobacco company launches foundation to stub out smoking [The Guardian] Philip Morris International say their Foundation for a Smoke-Free World aims to accelerate the end of smoking, but anti-tobacco campaigners are sceptical.
	3.3 Prévention - Vaccins
What's Next after Creating a Cancer-Prevention Vaccine? [Scientific American] One thing we are doing at the NCI, and cosponsored by the Bill & Melinda Gates Foundation, is testing if one dose of HPV vaccine is enough to provide long-term protection. It would be transformative, especially in the developing country setting.
	5. Traitements
FDA-approved drug may block resistance to anti-angiogenesis therapy [Mass. General Hospital] Mass. General study identifies targetable pathway that induces immunosuppressive environment in colorectal cancer.
	5.10 Traitements - Essais
Clinical trial matching platform raises $11M backed by Merck’s tech fund [FierceBiotech] Antidote says the system has helped patient recruitment for 14,000 clinical trials. The plan is quite ambitious: to cover all U.S. trials next year.
Pfizer and Astellas Announce Positive Top-Line Results from Phase 3 PROSPER Trial of XTANDI (enzalutamide) in Patients with Non-Metastatic Castration-Resistant Prostate Cancer [Astellas] Enzalutamide is the first androgen receptor-inhibitor to demonstrate a statistically significant improvement in metastasis-free survival (MFS) in this patient population in a randomized, controlled clinical trial.
	5.12 Immunothérapies
Can the culprit for cancer spreading also boost immuno-oncology treatments? [FierceBiotech] The discovery led by the Chicago team may make it possible to predict which patients will respond best to checkpoint inhibitors with a blood test prior to starting treatment, the researchers say. VEGF-C is “easy to measure from a blood sample.
	5.12.1 Immunothérapies - partenariats
Seeking an edge in a fiercely-fought field, Bristol-Myers pays Halozyme $105M to access I-O delivery tech [FierceBiotech] Halozyme has landed deals with AbbVie, Eli Lilly, Johnson & Johnson, Pfizer and Roche on the strength of rHuPH20’s ability to unlock subcutaneous delivery.
Halozyme Inks $105M Bristol-Myers Partnership, Expands Roche Deal [Xconomy] The Roche deal announced Thursday builds on one of Halozyme’s longest business relationships. In 2006, Roche licensed Halozyme’s technology to develop up to 13 compounds. So far, the collaboration has yielded injectable formulations of Roche cancer drugs trastuzumab (Herceptin) and rituximab (MabThera).
Looking for an I/O edge, Bristol-Myers fronts $105M to partner with Halozyme as Roche expands pact [EndPoints] The San Diego-based biotech will lend its hyaluronidase enzyme (rHuPH20) — which temporarily degrades hyaluronan — to see if Bristol’s drugs can be delivered with a subcutaneous jab instead of by IV.
	5.2 Pharma
Hemo-oncology newbie Bayer gears up for copanlisib launch [FiercePharma] If Bayer can snag an FDA approval—based on phase 2 results that showed copanlisib could provoke a response in 58.7% of relapsed or refractory follicular lymphoma patients, completely ridding 14.4% of them of cancer—it’ll go up against Gilead’s Zydelig, a med in copanlisib’s PI3K class that’s also approved for patients who have received two or more therapies.
	5.4 Traitements - Economie
Drug Companies Tie Costs to Outcomes [Wall Street Journal] But early signs show little evidence that the plans lower prices.
	5.9 AACR
AACR Cancer Progress Report 2017: Harnessing Research Discoveries to Save Lives [Cancer Research Catalyst] The report highlights how federally funded research that provides a deep understanding of the biology of cancer is spurring advances across the clinical cancer care continuum that are improving survival and quality of life for people around the world.
	6.1 Observation
Childhood cancer survivors face lifetime of chronic health conditions [Reuters] The researchers looked at 168 chronic health conditions in 48 disease categories among 3,010 survivors over age 18 who were treated for cancer at St. Jude as children.
	6.11 Patients
Cancer patients know immuno-oncology and top drugs, but lack details: study [FiercePharma] The education gap could be an opportunity for pharma companies. Because today’s cancer therapies tend to have a wide range of results depending on each specific patient—with some of those results very disappointing—it may be in pharma’s best interest to manage expectations with more precise details.
	6.6 Publications
Making Peer Review More Transparent with Open Annotation [ORCID] By empowering peer review processes with the same basic tools that researchers use in writing and updating their manuscripts, Hypothesis harnesses the power of standards-based and interoperable technologies that fulfill the promise of the web.
	6.8 Communication
Worrisome ‘right to try’ legislation may soon become law. Here’s the story that some news outlets missed [HealthNewsReview] When hope sells, bad journalism becomes acceptable.
	6.9 Controverses
STAT becomes 3rd major organization to revise policies after our scrutiny [HealthNewsReview] In the new policy, STAT has addressed ghostwriting for the first time. That glaring problem was not addressed in their retraction of the original article.
This $25,000 Life-Extension Test Is Impressing Investors But Not Doctors [Bloomberg] “We’re driving a medical revolution,” says Venter of his latest startup, Human Longevity Inc., or HLI. “We have sequencing that’s better than anybody else in the world. We have the most accurate data.”